Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 0.60 |
| ▸ | CNR2 | P34972 | 4/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | GLP1R | P43220 | 1/20 | 0.37 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | ADGRF1 | Q5T601 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5336377 | 0.89 | CNR1 (0.64) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL5348907 | 0.87 | CNR1 (0.62) | CNR1CNR2MDM4MDM2ADRB2 | |
| SCHEMBL5336173 | 0.85 | CNR1 (0.57) | CNR1CNR2MDM4MDM2ADRB2 | |
| SCHEMBL5339080 | 0.85 | CNR1 (0.80) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL5345696 | 0.83 | CNR1 (0.61) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL5350892 | 0.81 | CNR1 (0.64) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL5340957 | 0.79 | CNR1 (0.62) | CNR1CNR2ADRB2ADRA2AAGTR1 | |
| SCHEMBL5349653 | 0.79 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL5386284 | 0.78 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL5335401 | 0.77 | CNR1 (0.64) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230024-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2007-06-12 | — | — | US | claimed |
| US-20060205948-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2006-09-14 | — | — | US | claimed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | claimed |
| US-7241788-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241788-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241788-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7230024-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230024-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230024-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2007-06-12 | — | — | US | disclosed |
| US-7145012-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20060205948-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2006-09-14 | — | — | US | disclosed |
| US-20060205720-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2006-09-14 | — | — | US | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205720-A1 | Cannabinoid receptor ligands and uses thereof | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885MDM4 4879/4885 |
| US-20060205948-A1 | Cannabinoid receptor ligands and uses thereof | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885MDM4 4879/4885 |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885MDM4 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.